François Candelon is the Global Director of BHI based in BCG’s Paris office and a Managing Director & Senior Partner. He also leads BHI’s Tech & Biz Lab focused on exploring the technology horizon and sharing actionable insights with leaders.
François’ research is focused on AI and Digital as a source of competitive advantage for businesses, national economies, and current research themes include topics such as AI competitiveness, deep tech, and AI & society.
His work has appeared in publications such as Harvard Business Review, MIT Sloan Management Review, Strategy Science, TED. He writes a monthly column on AI in Fortune and he has been a speaker at global conferences like Politico, AI Summit, MWC, TED, Web Summit, Global AI Summit, and Wuzhen Internet Conference. In 2021, he was among the 8 shortlisted for the prestigious Thinkers50 distinguished Digital Award.
Outside of work, Francois enjoys sports, karate, contemporary art, and theater.
The world’s top 20 internet companies come from just two countries — the US and China — and they show no signs of slowing down (think Amazon and Alibaba, respectively). We need a more equitable digital revolution to spread the wealth or else face massive global inequality, says BCG Fellow and senior partner François Candelon. His solution? To urge […]
As GPT-4 and other new models are released, leaders need to constantly assess the implications for their business.
This powerful technology has the potential to disrupt nearly every industry, promising both competitive advantage and creative destruction. Here’s how to strategize for that future.
Incumbents in many industries are experimenting with syn-bio engagement strategies. However, they can’t rely solely on traditional buying and selling relationships because the syn-bio ecosystem in still very nascent.
By analyzing the syn-bio industry stack and understanding its dynamics, incumbents can develop strategies that will gain them competitive advantage.
Prompt engineering is only the beginning—it’s time to start experimenting.
Advances in syn-bio depend on incumbent companies and startups working together and leveraging each others' strengths, only then can both generate all the benefits that the science promises.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |